Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells

BACKGROUND: T cell-redirecting bispecific antibodies (BsAbs) are emerging as a potent cancer therapy that crosslinks tumor cells and T cells by simultaneously binding to tumor-associated antigen and CD3ε. However, immune inhibitory molecules can be remarkably upregulated after BsAbs treatment, leadi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Mei, Wang, Hongmei, Zhou, Shujuan, Wei, Jia, Ding, Naiqing, Shao, Jie, Yu, Lixia, Feng, Zhenqing, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873023/
https://www.ncbi.nlm.nih.gov/pubmed/33574677
http://dx.doi.org/10.2147/OTT.S291086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873023/
https://www.ncbi.nlm.nih.gov/pubmed/33574677
http://dx.doi.org/10.2147/OTT.S291086

Ejemplares similares